Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Current seasonal influenza vaccines mainly target a different, more abundant influenza surface protein called hemagglutinin (HA). However, because influenza vaccines offer varying and sometimes limited protection, scientists are exploring ways to improve vaccine effectiveness. The new research builds on previous studies of NA and was conducted by a team of scientists including investigators from the Centers of Excellence for Influenza Research and Surveillance (CEIRS)program, which is organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Investigators analyzed blood samples from people vaccinated against influenza and people diagnosed with either the 2009 H1N1 influenza virus or H3N2 influenza viruses. The volunteers were recruited for this study or had taken part in prior influenza research studies. The analyses indicate that influenza vaccines rarely induce NA-reactive antibodies, whereas natural influenza infection induces these types of antibodies at least as often as they induce HA-reactive antibodies. Additional studies in mice reinforced the human data, indicating that current influenza vaccines do not induce NA-reactive antibodies efficiently.
Additional laboratory experiments show that the NA-reactive antibodies induced during natural influenza infection are broadly reactive, meaning they could potentially protect against diverse strains of influenza. To test this theory, scientists isolated NA-reactive monoclonal antibodies from the H3N2 and H1N1 influenza patients (N2-reactive antibodies and N1-reactive antibodies, respectively). They administered 13 N2-reactive antibodies to mice and subsequently infected the mice with a different H3N2 virus strain. Eleven of the 13 N2-reactive antibodies partially or fully protected the mice. They also administered eight N1-reactive antibodies to mice and subsequently infected the mice with a similar H1N1 virus strain or an H5N1-like virus strain. Four of the eight antibodies completely protected the mice against both virus strains.
The authors note that the findings suggest that influenza vaccines should be optimized to better target NA for broad protection against diverse influenza strains. In this regard, NIAID is supporting research to characterize NA responses in infected and vaccinated individuals and to determine the mechanism of action of NA protection. NIAID also supports “NAction!” a CEIRS working group that identifies knowledge gaps in our understanding of NA and sets NA research priorities for improved influenza vaccines. These efforts contribute to NIAID’s larger plan to develop a universal influenza vaccine—a vaccine that can durably protect all age groups against multiple influenza virus strains.
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Life-saving vaccine scientist's 100th birthday celebratedon September 7, 2019 at 3:13 am
He would grow up to develop vaccines against measles, mumps, chickenpox, pneumonia, influenza, meningitis and hepatitis and other diseases. Hilleman is credited with saving tens of millions of lives ...
- Disrupting the gut microbiome may affect some immune responses to flu vaccinationon September 6, 2019 at 4:50 pm
Researchers have now found that oral antibiotics, which can kill gut microorganisms, can alter the human immune response to seasonal influenza vaccination. The normal human gut microbiome is a ...
- Patterns of seasonal and pandemic influenza-associated health care and mortality in Ontario, Canadaon September 6, 2019 at 7:01 am
Mathematical and statistical models are used to project the future time course of infectious disease epidemics and the expected future burden on health care systems and economies. Influenza is a ...
- Epidemiological and clinical characteristics of children hospitalized due to influenza A and B in the south of Europe, 2010–2016on September 6, 2019 at 2:22 am
Influenza produces annual epidemics that affect 5–15% of the world population. Complications and hospitalizations are more frequent in childhood. This study describes and analyses the epidemiological ...
- Avian Influenza Vaccines Sales Market 2019 Outlook, Opportunity and Demand Analysis Report by 2024on September 5, 2019 at 7:54 am
Sep 05, 2019 (Heraldkeepers) -- New York, September 05, 2019: Market Research Engine has published a new report titled as "Avian Influenza Vaccines Sales Market By Application (Chicken, Duck & ...
- Influenza Diagnostics Market 2019 Global Industry Share, Size Estimation, Demand, Trend, Challenges, Comprehensive Insights, Future Forecasts To 2023on September 4, 2019 at 6:25 pm
The Global Influenza Diagnostics Market is Expected to Register a CAGR of 7.80% to reach USD 954.512 million by 2023. The key players identified in the global influenza diagnostics market are Abbott, ...
- Structures of influenza A virus RNA polymerase offer insight into viral genome replicationon September 4, 2019 at 10:07 am
Fig. 2: Mutations at the interface of the FluPol A dimer inhibit cRNA to vRNA replication. Fig. 3: Structures of H3N2 FluPol A bound to cRNA promoter. Fig. 4: Nb8205, which binds FluPol A at the dimer ...
- Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conferenceon September 3, 2019 at 5:05 am
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50
- Seasonal Influenza Vaccine Market Size Research Report | Growth Forecast 2025on September 2, 2019 at 6:22 am
Sep 02, 2019 (AmericaNewsHour) -- Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, ...
via Bing News